{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Apellis Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Apellis Pharmaceuticals has shifted to a neutral trend with mixed signals, underperforming the S&P 500 significantly, showing a year-to-date return of -35.16% compared to the index's 16.30%.
Is Apellis Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Apellis Pharmaceuticals, Inc. has shifted to a neutral technical stance with mixed indicators, showing a year-to-date decline of 32.72%, underperforming the S&P 500's gain of 16.30%.
Is Apellis Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Apellis Pharmaceuticals, Inc. shows a neutral technical trend with a mildly bearish outlook on weekly indicators, while significantly underperforming the S&P 500 with a year-to-date return of -32.72%.
Apellis Pharmaceuticals Hits Day Low of $20.66 Amid Price Pressure
Apellis Pharmaceuticals, Inc. has faced significant stock volatility, hitting an intraday low and experiencing notable declines over various time frames. The company reports a substantial net loss and high leverage, with ongoing financial pressures reflected in its negative return on equity. Its performance continues to attract scrutiny within the industry.
Apellis Pharmaceuticals Faces Weak Start with 17.3% Gap Down Amid Market Concerns
Apellis Pharmaceuticals, Inc. experienced a notable decline in its stock performance, contrasting with the stable S&P 500. The company, with a market capitalization of approximately USD 3.4 billion, faces financial challenges, including a negative return on equity and no dividend yield, amid mixed technical indicators.
Apellis Pharmaceuticals Stock Hits Day High with 8.94% Surge
Apellis Pharmaceuticals, Inc. saw a notable increase in its stock today, contrasting with a slight decline in the S&P 500. While the company has shown modest gains over the past week and month, it faces significant challenges, including a year-to-date decline and ongoing financial pressures.
Apellis Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout
Apellis Pharmaceuticals has recently achieved a Golden Cross, indicating a potential shift in momentum. Current technical indicators present a mixed outlook, with varying bullish and bearish signals. Despite a year-long performance decline, the stock has shown short-term gains, prompting interest in its future trading dynamics.
Is Apellis Pharmaceuticals, Inc. technically bullish or bearish?
As of July 7, 2025, Apellis Pharmaceuticals shows a mildly bearish trend with mixed technical indicators, including bullish weekly MACD and bearish daily moving averages, while significantly underperforming the S&P 500 year-to-date and over the past year.
Is Apellis Pharmaceuticals, Inc. overvalued or undervalued?
As of February 25, 2021, Apellis Pharmaceuticals is considered risky and overvalued due to high valuation ratios and poor performance, including a YTD return of -26.73% and an ROE of -135.02%.
Is Apellis Pharmaceuticals, Inc. technically bullish or bearish?
As of June 27, 2025, the market trend is bearish with moderate strength, supported by daily moving averages and weekly Bollinger Bands, despite some mixed signals from the MACD and KST.
Is Apellis Pharmaceuticals, Inc. overvalued or undervalued?
As of February 25, 2021, Apellis Pharmaceuticals is rated as "risky" and overvalued, with key ratios indicating poor performance compared to peers, including a Price to Book Value of 14.76 and a year-to-date return of -44.78%, significantly lagging behind the S&P 500's 2.44%.
Is Apellis Pharmaceuticals, Inc. technically bullish or bearish?
As of June 5, 2025, the market trend is mildly bearish, influenced by daily moving averages and Bollinger Bands indicating bearish momentum, while mixed signals from weekly and monthly MACD and KST suggest some counterbalance.
Who are in the management team of Apellis Pharmaceuticals, Inc.?
As of March 2022, the management team of Apellis Pharmaceuticals, Inc. includes Dr. Cedric Francois as CEO and several independent directors, including Dr. Gerald Chan (Chairman), Mr. A. Sinclair Dunlop, Mr. Paul Fonteyne, Mr. Alec Machiels, and Ms. Stephanie O'Brien.
What does Apellis Pharmaceuticals, Inc. do?
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. As of March 2025, it has a market cap of approximately $2.23 billion, with net sales of $167 million and a net loss of $92 million.
How big is Apellis Pharmaceuticals, Inc.?
As of Jun 18, Apellis Pharmaceuticals, Inc. has a market capitalization of $2.23 billion, with net sales of $775.85 million and a net profit of -$223.68 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
